Monday - April 20, 2026
Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer
April 19, 2026
PHILADELPHIA, Pennsylvania, April 19 [Category: Medical] -- The American Association for Cancer Research posted the following news release:

* * *

Next-generation KRAS G12C Inhibitor Elisrasib Elicited Promising Response Rates in Patients With Advanced Lung Cancer

*

Responses were seen in patients who were not treated with prior KRAS G12C inhibitors as well as those whose disease progressed on prior KRAS G12C inhibitors

SAN DIEGO - . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products